Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse

Journal of Neurology

Volumn 263, Issue 8, 2016, Pages 1641-1651

  Jongen, Peter Joseph ^a,b   Stavrakaki, Ioanna ^c   Voet, Bernard ^d   Hoogervorst, Erwin ^e   van Munster, Erik ^f   Linssen, Wim H ^g   Sinnige, Ludovicus G ^h   Verhagen, Wim I ⁱ   Visser, Leo H ^j   van der Kruijk, Ruud ^k   Verheul, Freek ^l   Boringa, Jan ^m   Heerings, Marco ⁿ   Gladdines, Werner ^c   Lönnqvist, Fredrik ^c   Gaillard, Pieter ^c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MS4 Research Institute   (Netherlands)

^c BBB Technologies BV   (Netherlands)

^d St Antonius Hospital ^*  (Germany)

^e ST ANTONIUS HOSPITAL   (Netherlands)

^f JEROEN BOSCH HOSPITAL   (Netherlands)

^g ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^h MEDICAL CENTER LEEUWARDEN   (Netherlands)

ⁱ CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^j Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

^k SLINGELAND HOSPITAL   (Netherlands)

^l GROENE HART HOSPITAL   (Netherlands)

^m MEANDER MEDICAL CENTER   (Netherlands)

ⁿ MH advies and Organisatiebureau   (Netherlands)

more..

Author keywords

Adverse effect; High dose; Methylprednisolone; Multiple sclerosis; Patient reported; Side effect

Indexed keywords

METHYLPREDNISOLONE; ANTIINFLAMMATORY AGENT;

ACNE; ADULT; AGITATION; APPETITE; ARTICLE; BEHAVIOR CHANGE; DAILY LIFE ACTIVITY; DEPRESSION; DISEASE SEVERITY; DRUG MEGADOSE; FACIAL FLUSHING; FEMALE; FLUSHING; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCLE CRAMP; MUSCLE WEAKNESS; OBSERVATIONAL STUDY; OPTIMISM; PERSONAL EXPERIENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RELAPSE; SELF REPORT; SIDE EFFECT; SLEEP DISORDER; STOMACH PAIN; TASTE; TEMPERAMENT; TREATMENT DURATION; WOUND HEALING IMPAIRMENT; AGED; CLINICAL TRIAL; DISABLED PERSON; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; ONLINE SYSTEM; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA;

ACTIVITIES OF DAILY LIVING; ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; DISABLED PERSONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; ONLINE SYSTEMS; PROSPECTIVE STUDIES; SELF REPORT; SURVEYS AND QUESTIONNAIRES;

EID: 84976320726     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-016-8183-3     Document Type: Article

References (30)

1. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121–127
2. Bejaoui K, Rolak LA (2010) What is the risk of permanent disability from a multiple sclerosis relapse? Neurology 74(11):900–902. doi:10.1212/WNL.0b013e3181d55ee9
3. Sellebjerg F, Barnes D, Filippini G, Midgard R, Montalban X, Rieckmann P, Selmaj K, Visser LH, Sorensen PS (2005) EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol Off J Eur Fed Neurol Soc 12(12):939–946. doi:10.1111/j.1468-1331.2005.01352.x
4. Schacke H, Docke WD, Asadullah K (2002) Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96(1):23–43
5. Elixhauser A, Owens P (2006) Adverse Drug Events in US Hospitals, 2004: Statistical Brief #29. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD)
6. Troiano R, Cook SD, Dowling PC (1987) Steroid therapy in multiple sclerosis. Point of view. Arch Neurol 44(8):803–807
7. Bren L (2006) The importance of patient-reported outcomes…it’s all about the patients. FDA Consum 40(6):26–32
8. Fardet L, Flahault A, Kettaneh A, Tiev KP, Genereau T, Toledano C, Lebbe C, Cabane J (2007) Corticosteroid-induced clinical adverse events: frequency, risk factors and patient’s opinion. Br J Dermatol 157(1):142–148. doi:10.1111/j.1365-2133.2007.07950.x
9. Guidry JA, George JN, Vesely SK, Kennison SM, Terrell DR (2009) Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives. Eur J Haematol 83(3):175–182. doi:10.1111/j.1600-0609.2009.01265.x
10. Ramo-Tello C, Grau-Lopez L, Tintore M, Rovira A, RamioiTorrenta L, Brieva L, Cano A, Carmona O, Saiz A, Torres F, Giner P, Nos C, Massuet A, Montalban X, Martinez-Caceres E, Costa J (2014) A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. Mult Scler 20(6):717–725. doi:10.1177/1352458513508835
11. Chataway J (2014) Oral versus intravenous steroids in multiple sclerosis relapses—a perennial question? Mult Scler 20(6):643–645. doi:10.1177/1352458514531088
12. Act Sport MoHWa Dutch Medical Research Involving Human Subjects, (WMO) (1999) International Publication Series Health. Welfare and Sport 2:1–34
13. Shaygannejad V, Ashtari F, Alinaghian M, Norouzi R, Salari M, Fatehi F (2013) Short-term safety of pulse steroid therapy in multiple sclerosis relapses. Clin Neuropharmacol 36(1):1–3. doi:10.1097/WNF.0b013e3182764f91
14. Wynia K, Middel B, van Dijk JP, de Ruiter H, de Keyser J, Reijneveld SA (2008) The Multiple Sclerosis impact Profile (MSIP). Development and testing psychometric properties of an ICF-based health measure. Disabil Rehabil 30(4):261–274. doi:10.1080/09638280701256868
15. Wynia K, Middel B, de Ruiter H, van Dijk JP, de Keyser JH, Reijneveld SA (2008) Stability and relative validity of the Multiple Sclerosis Impact Profile (MSIP). Disabil Rehabil 30(14):1027–1038
16. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452
17. Le Page E, Veillard D, Laplaud DA, Hamonic S, Wardi R, Lebrun C, Zagnoli F, Wiertlewski S, Deburghgraeve V, Coustans M, Edan G (2015) Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet 386(9997):974–981. doi:10.1016/S0140-6736(15)61137-0
18. Luhder F, Reichardt HM (2009) Traditional concepts and future avenues of glucocorticoid action in experimental autoimmune encephalomyelitis and multiple sclerosis therapy. Crit Rev Immunol 29(3):255–273
19. Stuart FA, Segal TY, Keady S (2005) Adverse psychological effects of corticosteroids in children and adolescents. Arch Dis Child 90(5):500–506. doi:10.1136/adc.2003.041541
20. Kelly WF, Kelly MJ, Faragher B (1996) A prospective study of psychiatric and psychological aspects of Cushing’s syndrome. Clin Endocrinol 45(6):715–720
21. Koehler PJ (1995) Use of corticosteroids in neuro-oncology. Anticancer Drugs 6(1):19–33
22. Weusten BL, Jacobs JW, Bijlsma JW (1993) Corticosteroid pulse therapy in active rheumatoid arthritis. Semin Arthritis Rheum 23(3):183–192
23. Yamasaki R, Matsushita T, Fukazawa T, Yokoyama K, Fujihara K, Ogino M, Yokota T, Miyamoto K, Niino M, Nomura K, Tomioka R, Tanaka M, Kawachi I, Ohashi T, Kaida KI, Matsui M, Nakatsuji Y, Ochi H, Fukaura H, Kanda T, Nagaishi A, Togo K, Mizusawa H, Murai H, Kira JI (2015) Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica. Mult Scler. doi:10.1177/1352458515617248
24. Lienert C, Schawalder G, Findling O, Kamm CP, Humpert S, Mugglin A, Mathis J, Sturzenegger M, Mattle HP (2013) Tolerance of intravenous methylprednisolone for relapse treatment in demyelinating CNS disease. Swiss Med Wkly 143:w13783. doi:10.4414/smw.2013.13783
25. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O’Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stuve O, Waubant E, Polman CH (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83(3):278–286. doi:10.1212/WNL.0000000000000560
26. Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, Kovac SH, Spettell CM, Saag KG (2006) Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 55(3):420–426. doi:10.1002/art.21984
27. Caster O, Edwards IR (2015) Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses. BMC Neurol 15:206. doi:10.1186/s12883-015-0450-x
28. Kalincik T (2015) Multiple Sclerosis relapses: epidemiology, outcomes and management. A systematic review. Neuroepidemiology 44(4):199–214. doi:10.1159/000382130
29. Asano M, Hawken K, Turpin M, Eitzen A, Finlayson M (2015) The lived experience of multiple sclerosis relapse: how adults with multiple sclerosis processed their relapse experience and evaluated their need for postrelapse care. Mult Scler Int 2015:351416. doi:10.1155/2015/351416
30. Oleen-Burkey M, Castelli-Haley J, Lage MJ, Johnson KP (2012) Burden of a multiple sclerosis relapse: the patient’s perspective. Patient 5(1):57–69. doi:10.2165/11592160-000000000-00000